Clinical Trials Logo

Clinical Trial Summary

In the absence of 2019-ncov specific therapeutic drugs, arbidol is effective against a variety of coronaviruses in vitro pharmacodynamics. In order to observe the efficacy and safety of arbidol in the treatment of 2019-ncov infected pneumonia, this study is planned.


Clinical Trial Description

In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (2019-nCoV) from these pneumonia patients and developed a real-time reverse transcription PCR (real time RT-PCR) diagnostic assay. The number of cases of infection with 2019-nCoV identified in Wuhan increased markedly over the later part of January 2020, with cases identified in multiple other Provinces of China and internationally. Mathematical models of the expansion phase of the epidemic suggested that sustained person-to-person transmission is occurring, and the R-zero is substantially above 1, the level required for a self-sustaining epidemic in human populations. There is currently no specific treatment for 2019-ncov-infected pneumonia. Arbidol tablet is a non-nucleoside broad-spectrum antiviral drug with immune-enhancing effect. Abidor is pharmacodynamic in vitro against a variety of coronaviruses.This is a randomized, open, multicenter clinical study of pneumonic subjects diagnosed with 2019-ncov infection. The main objective was to compare the viral negative conversion rate in the first week after the subjects were randomized to arbidol plus basic treatment. In this study, 380 eligible patients with pneumonia diagnosed with 2019-ncov infection were randomly assigned to one of two treatment groups at a 1:1 ratio. patients will receive one of two treatment regimens: A .Abidor tablets + basic treatment B. basic treatment Arbidol tablets: take 2 tablets/time, 3 times/day for 14-20 days Basic treatment :The basic treatment used by the investigator was based on the condition of the patient. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04260594
Study type Interventional
Source Ruijin Hospital
Contact
Status Completed
Phase Phase 4
Start date February 8, 2020
Completion date December 30, 2020

See also
  Status Clinical Trial Phase
Suspended NCT04334967 - Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care Phase 4
Not yet recruiting NCT04264858 - Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients N/A
Withdrawn NCT04272710 - Prognositc Factors in COVID-19 Patients Complicated With Hypertension
Active, not recruiting NCT04273763 - Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) N/A
Not yet recruiting NCT04270383 - Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children
Terminated NCT04261907 - Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection N/A
Not yet recruiting NCT04261426 - The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia Phase 2/Phase 3
Recruiting NCT04255017 - A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia Phase 4
Recruiting NCT04254874 - A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia Phase 4
Not yet recruiting NCT04356508 - COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1 Phase 2
Terminated NCT04321928 - Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary N/A